Compare iShares Silver Trust (SLV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Silver Trust trades at $59.22, while State Street SPDR S&P Biotech ETF trades at $159.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | XBI | |
|---|---|---|
52-Week High | $105.57 | $164.28 |
52-Week Low | $33.89 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $59.24, down 0.29% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, though prices eased ahead of CPI data. Financial ratios are unavailable as SLV is an ETF tracking physical silver, not a company with earnings.
The outlook for SLV hinges on silver's industrial and monetary demand, with support from AI infrastructure needs and potential Fed dovishness. Risks include dollar strength, inflation data surprises, and volatility from leveraged ETF comparisons. Investors gain pure silver exposure without mining operational risks.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
